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ABSTRACT
Breast cancer is a heterogeneous disease with several subtypes carrying unique 
prognoses. Patients with differentiated luminal tumors experience better outcomes, 
while effective treatments are unavailable for poorly differentiated tumors, including 
the basal-like subtype. Mechanisms governing mammary tumor subtype generation 
could prove critical to developing better treatments. C-Jun N-terminal kinase 2 
(JNK2) is important in mammary tumorigenesis and tumor progression. Using 
a variety of mouse models, human breast cancer cell lines and tumor expression 
data, studies herein support that JNK2 inhibits cell differentiation in normal and 
cancer-derived mammary cells. JNK2 prevents precocious pubertal mammary 
development and inhibits Notch-dependent expansion of luminal cell populations. 
Likewise, JNK2 suppresses luminal populations in a p53-competent Polyoma Middle 
T-antigen tumor model where jnk2 knockout causes p53-dependent upregulation of 
Notch1 transcription. In a p53 knockout model, JNK2 restricts luminal populations 
independently of Notch1, by suppressing Brca1 expression and promoting epithelial 
to mesenchymal transition. JNK2 also inhibits estrogen receptor (ER) expression and 
confers resistance to fulvestrant, an ER inhibitor, while stimulating tumor progression. 
These data suggest that therapies inhibiting JNK2 in breast cancer may promote 
tumor differentiation, improve endocrine therapy response, and inhibit metastasis.
INTRODUCTION
In the pubertal mammary gland, ductal branches 
invade and extend into the fat pad guided by transient 
bulbous structures called terminal end buds (TEBs). 
Mammary stem and progenitor cells reside in TEBs 
while differentiated, apical luminal cells and basally 
located myoepithelial cells form the duct as extension 
proceeds. During this process, mammary stem cells 
respond to stimuli that facilitate commitment into 
luminal or basal lineages. Current evidence suggests 
that mammary stem and/or luminal progenitor cells are 
the probable targets for breast cancer development [1–3]. 
Thus, it is important to interrogate these populations to 
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understand how cell differentiation affects susceptibility to 
transformation or tumor progression. Insight into integral 
differentiation pathways may provide opportunities for 
new treatments with the goal of targeting tumor initiating 
cells, which having undergone epithelial to mesenchymal 
transition (EMT), promote treatment resistance, tumor 
recurrence and metastasis.
Multiple pathways contribute to mammary 
lineage commitment in both normal and tumor cells. 
Of the four Notch receptors, Notch1 shows the highest 
abundance in luminal cells [4]. Notch1 enhances luminal 
populations  [4–6]  whereas,  its  counterpart  ΔNp63  is 
highly expressed in basal populations. In the normal 
mammary gland, Notch1 and ΔNp63 regulate each other’s 
expression in opposing fashions to sustain a homeostatic 
balance between luminal and myoepithelial cell 
populations. In breast tumors, persistent Notch1 activity 
in tumor initiating or progenitor cells may have a negative 
impact on tumor progression [7, 8].
Similar to Notch1, BRCA1 is critical for 
differentiation of progenitors into ER+ luminal cells [9]. 
BRCA1 induces ER transcription [10] and inhibits 
transcriptional machinery associated with de-differentiation 
and EMT [1, 11]. A high proportion of mutant BRCA1 
breast tumors are classified as basal-like, [12–14], likely 
because mutations in BRCA1 block terminal differentiation 
and cause luminal progenitor expansion. Experimental 
transformation of these progenitors generates tumors 
that  closely  reflect  those  of  BRCA1  mutation  carriers 
with  basal-like  features  [1–3].  Aside  from  hereditary 
breast cancer, low BRCA1 expression occurs in sporadic 
breast cancers by means of promoter methylation or 
overexpression of transcriptional repressors [15, 16]. 
These studies suggest that a reduction in wildtype protein 
inhibits mammary cell differentiation. While recognized 
as  a  critical  player  in  breast  cancer  risk  and  behavior, 
no approaches have been developed to enhance BRCA1 
function in breast cancer to improve patient outcome. 
Correspondingly, therapeutically targeting basal and tumor 
initiating cells with EMT properties is challenging due to 
their low proliferative index. These findings emphasize the 
need to identify “druggable” targets that control mammary 
cell differentiation.
JNK1  and  JNK2  isoforms  are  ubiquitously 
expressed. Through phosphorylation of various substrates, 
most notably c-Jun, JNKs govern apoptosis, proliferation, 
motility,  and  differentiation.  Knockout  or  knockdown 
of  JNK2  inhibits  mammary  tumor  cell  migration  and 
invasion along with tumor growth and metastasis in 
response to receptor tyrosine kinases [17, 18]. High JNK2 
expression in human basal-type tumors is also associated 
with shorter disease free survival [17]. These key results 
motivated us to explore novel roles of JNK2 in normal and 
cancer related cell lineage commitment.
Using jnk2 knockout (jnk2ko) mice and cell lines, 
we  develop  a  model  by  which  JNK2  inhibits  luminal 
differentiation in normal and cancerous mammary 
epithelial cells through two mechanisms that depend on 
p53  status.  In  p53  competent  cells,  JNK2  lowers  p53 
expression,  and  consequently  Notch1  expression,  to 
limit luminal populations. In the absence of p53, JNK2 
prevents luminal differentiation by inhibiting BRCA1 and 
ER expression. Through these diverse means, it serves 
a central role in mammary cell lineage commitment and 
enhances tumor initiating cells and metastasis. These 
results suggest that targeting JNK2 in breast tumors may 
expand the population of therapy sensitive cells and 
consequently improve patient outcomes.
RESULTS
Jnk2 loss causes precocious mammary 
development and alters mammary 
epithelial cell differentiation
To  investigate  if  JNK2  affects  mammary 
development, glands were harvested from female jnk2wt 
and jnk2ko  virgin  mice.  By  five  weeks  of  age,  ductal 
development of whole-mounted jnk2ko pubertal glands 
appear more advanced than jnk2wt glands as evidenced 
by ductal extension (Fig 1A and 1B, p = 0.012), increased 
secondary branching (Fig 1C, p = 0.0169), and increased 
number of TEBs (Fig 1D, p < 0.0001). By the end of 
puberty, glands of both genotypes completely fill the fat 
pad.  These  quantifications  confirm  that  jnk2ko glands 
exhibit precocious pubertal development.
Analysis of adult jnk2wt glands shows that JNK2 is 
widely expressed in mammary epithelial cells (Fig 1SA). 
When  staining  for  cell  lineage markers,  jnk2ko glands 
possess 35% fewer p63+ basal/myoepithelial cells than 
jnk2wt (Fig 1E, p = 0.0078 and Fig 1SB) with a reciprocal 
increase in ER+ cells (Fig 1F, p = 0.011 and Fig 1SC). 
Higher  cytokeratin  (CK)8/18  expression  in  jnk2ko 
organoids is shown by western blot (Fig 1G). To better 
quantify  the  luminal  and  basal  cell  populations,  cell 
surface markers CD49f and CD24 were measured using 
flow cytometry. Jnk2ko glands contain 61% lin-/CD49fLo/
CD24+ luminal cells compared to 36% in jnk2wt glands 
(Fig 1H). This corresponds to a smaller basal population 
in the jnk2ko mammary epithelial cells.
Given that jnk2 encodes a ubiquitously expressed 
protein and its deletion may lead to hormone-dependent 
alterations in mammary cell differentiation, we explored 
whether it could function cell autonomously in 3D 
organoid culture. Consistent with in vivo observations, 
the resulting jnk2ko acini show fewer smooth muscle 
actin (SMA)+ basal cells and more CK8/18+ luminal cells 
compared to the jnk2wt controls (Fig 1I, 1J). Moreover, 
the average acinar diameter is greatly enhanced in jnk2ko 
group (Fig S1D, p < 0.0001). While proliferation did not 
significantly differ (Fig S1E, p = NS), apoptosis indices 
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did as evidenced by cleaved caspase 3 (Fig S1F, 
p  =  0.0009),  perhaps  a  consequence  of  precocious 
hollowing of jnk2ko acini. Together, these data support 
that JNK2 alters basal and luminal proportions in a cell 
autonomous fashion.
JNK2 inhibits normal luminal mammary 
differentiation in a Notch1-dependent fashion
Differentiation and development of the mammary 






















































































































































Figure 1: Absence of JNK2 accelerates pubertal mammary development and alters mammary cell differentiation.  
A. Representative whole mounts of mammary glands from jnk2wt and jnk2ko mice at puberty (5 wk-old); B-D. Quantification of ductal 
extension, branching, and total terminal end buds from pre-puberty (3wk-old) and puberty (n = 5); E-F. Quantification of p63+ basal cells 
and ER+ luminal cells in adult ducts (n = 3); G. Western blot of CK8/18 expression in adult mammary organoids; H. Representative CD24 
and CD49f staining of adult mammary cells; I-J. Representative images of Smooth Muscle Actin (SMA)+ and CK8/18+ in 3D cultures. 
Nonparametric t-tests were performed for all analyses except Linear Regression analysis was used for D. *p < 0.05, **p < 0.001, 
***p < 0.0001.
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if Notch promotes proliferation and/or differentiation of 
jnk2ko mammary epithelial cells, 3D organoid cultures 
were treated with Gamma Secretase Inhibitor (GSI) 
IX, a pan inhibitor of Notch cleavage/activation. After 
11 days of GSI treatment, the proportion of p63+ basal 
cells in jnk2ko cultures significantly increases (Fig 2A and 
Fig S2A, p = 0.0006), and CK8/18+ populations decrease 
compared  to  vehicle  controls  (Fig  2B, p  =  0.0092  and 
Fig  S2B),  suggesting  a  greater  dependence  on  Notch 
signaling for luminal commitment compared to jnk2wt 
controls where no significant changes were observed.
These  findings  were  validated  by  inhibiting 
Notch-dependent transcription with a dominant 
negative  AdMAM51  [20]  in  3D  organoid  culture. 
In this experiment, mammary epithelial cells were 
isolated and infected with AdGFP (Adenoviral GFP) 
or AdMAM51 then placed in culture. RNA later 
harvested from cultures show AdMAM51 reduces 
expression of Hes1 in both genotypes (Fig 2C). Similar 
to GSI, AdMAM51 expression in jnk2ko mammary cells 
significantly decreases luminal CK8/18+ cell populations 
of jnk2ko  cultures  without  significantly  affecting 
populations in jnk2wt  cultures  (Fig  2D,  p = 0.0111 
and Fig 2SC). AdMAM51 also significantly reduces acinar 
diameter only in the jnk2ko cells (Fig 2E, p < 0.0001).
Notch reporter transgenic mice reveal that 
endogenous Notch activity is high in the pubertal 
gland [8]. Notch signaling was assessed by Notch1 
intracellular domain (Notch1ICD) immunohistochemistry 
of mammary glands from mice in puberty. A significantly 
higher proportion of TEB cells stain positive in 
jnk2ko glands as compared to jnk2wt controls (Fig 2F, 
p = 0.0159 and Fig 2SD), but no differences in Notch1ICD 
expression were detected in mature ducts. Localization 
of high Notch1ICD is important because it allows greatest 
influence over differentiation and is also consistent with 
reported endogenous Notch activity being highest in 
TEBs [8].
To test if increased Notch1ICD staining in jnk2ko 
pubertal glands leads to higher Notch-dependent 
transcription, Hes1 expression was measured, using 
qPCR.  Jnk2ko organoids express 10.5 times more 
Hes1 mRNA than jnk2wt  (Fig  2G,  p = 0.0093). 
Notch-1 mRNA is 6.4 times higher in jnk2ko organoids 
(Fig  2H,  p < 0.0001), along with an increase in full-


























































































































































































Figure 2: Elevated Notch1 in jnk2ko glands and mammary cells increases luminal cell populations. A-C. 3D cultures were 
grown in the presence of Gamma Secretase Inhibitor (GSI) or DMSO and probed for p63+ basal A or CK8/18+ luminal cells B; C Isolated 
mammary cells in suspension were infected with adenoviral vectors encoding GFP (AdGFP) or AdMAM51 and grown in 3D culture. Hes1 
expression was measured by qPCR in harvested cultures; D. CK8/18+ luminal cells were assessed by immunofluorescence in 3D cultures; 
E. Acinar diameter of 3D cultures was determined; G. Pubertal glands were probed for Notch1-ICD and analyzed within terminal end 
buds; F-H. Organoid RNA was analyzed for Hes1 G and Notch1 H expression using qPCR; I. Western blot of Notch1 protein in organoid 
samples. 1 Way ANOVA with post-hoc t-test was performed. Post-hoc nonparametric t-test was also performed for *p < 0.05, **p < 0.001, 
***p < 0.0001.
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Collectively, these data show that jnk2ko mammary 
epithelial cells are more sensitive to Notch signaling, and 
JNK2 regulates mammary epithelial cell differentiation 
via the Notch pathway.
Jnk2 loss increases the proportion of luminal cells 
in polyoma middle T antigen (MT) mammary 
tumors in a p53/Notch1-dependent fashion
The importance of decisive differentiation pathways 
in the normal gland in tumor differentiation is illustrated 
by the finding that basal-type tumors may originate from 
luminal progenitors rather than basal/myoepithelial 
cells  [2].  To  explore  whether  JNK2  affects  tumor  cell 
differentiation, we used an MT transgenic mouse model. MT 
tumors most closely reflect the phenotypic characteristics 
of human luminal breast cancer [21], [22]. MT/jnk2wt and 
MT/jnk2ko mammary tumors were immunostained with 
p63 or CK8/18 antibodies to identify basal and luminal 
cells, respectively. Although a high proportion of tumor 
cells do not express either marker, MT/jnk2ko tumors have 
significantly  fewer p63+ nuclei and more CK8/18+ cells 
(Fig 3A and 3B, p = 0.0079 and p = 0.0411 respectively). 









































































































































































































































































Figure 3: Absence of jnk2 in MT tumors increases luminal cell populations and enhances p53 and Notch1 expression.  
A-B. Representative images and quantification of p63+ A or CK8/18+ B cells in MT tumors (n = 5 per genotype); C. Representative images 
of Notch1ICD+  cells  in MT  tumors; D. Notch1 expression by qPCR  in MT  tumors; E-F. Hes1 E and Notch1 F expression by qPCR  in 
MT/jnk2ko cells; G. Western blot of full-length Notch1 in MT/jnk2ko GFP and GFP-JNK2 cells; H. p53 expression in MT/jnk2ko GFP and 
GFP-JNK2 cells by qPCR; I. p53 expression in normal mammary organoids by qPCR; J. MT/jnk2ko cells were transfected with Notch1 
promoter constructs and analyzed for promoter activity (N1PR= wildtype Notch1 promoter, N1PRp53mut = Notch1 promoter with mutated 
p53  response  elements, N1PRless  =  promoter-less  control  plasmid); K. Chromatin Immunoprecipitation assay of p53 binding to p53 
response elements within the p21 and Notch1 promoters in MT/jnk2ko cells. Gapdh promoter used as negative control. 1 Way ANOVA with 
post-hoc t-test was performed for J followed by post-hoc t-test. Nonparametric t-test was performed for all others, *p < 0.05, **p < 0.001.
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all cells, whereas MT/jnk2wt tumors are nearly void of 
its expression, (Fig 3C). Correspondingly, MT/jnk2ko 
tumors express four-fold higher Notch1 mRNA (Fig 3D, 
p = 0.0101). These results suggest that, akin to the normal 
mammary gland, JNK2 inhibits luminal cell populations in 
the spontaneous MT tumor model.
To  explore  the  mode  by  which  JNK2  inhibits 
Notch1 expression and activity, we used a MT/jnk2ko cell 
line expressing GFP-JNK2 or GFP alone [23]. Consistent 
with JNK2 suppression of Notch1 signaling, Hes1 mRNA 
is reduced GFP-JNK2 cells (Fig 3E, p = NS). Additionally, 
MT/jnk2ko GFP-JNK2 cells express less Notch-1 mRNA 
(p = 0.0005) and protein than MT/jnk2ko GFP cells 
(Fig 3F and 3G).
p53 potentiates Notch-1 transcription by binding 
to two p53 responses elements (REs) within its 
promoter [24]. Because MT tumors and cell lines express 
wildtype p53 [23], we hypothesized that JNK2 inhibits 
Notch1 in a p53-dependent fashion. This hypothesis is 
supported by the lower expression levels of p53 mRNA 
in MT/jnk2ko cells expressing GFP-JNK2 (Fig 3H) and 
the presence of nearly three times more p53 mRNA in 
jnk2ko mammary organoids compared to jnk2wt (Fig 3I, 
p = 0.0004).
A potential relationship between JNK2 and p53 in 
regulating Notch1 expression was then tested. MT/jnk2ko 
GFP and GFP-JNK2 cells were transfected with luciferase 
plasmids containing either full-length Notch1 promoter 
(N1PR), Notch1 promoter with mutated p53REs 
(N1PRmut), or promoterless (N1PRless), as previously 
described  [24]. As  expected,  JNK2  expression  reduces 
N1PR activity (Fig 3J, p = 0.0170). Further, only the GFP 
cells show reduced N1PRmut promoter activity compared 
to N1PR, supporting a mechanism whereby JNK2 inhibits 
Notch1 promoter activity by decreasing p53 expression or 
promoter binding.
To test if lower p53 expression in MT/jnk2ko GFP-
JNK2 cells leads to decreased p53 binding to the Notch1 
promoter, chromatin immunoprecipitation was performed. 
The p21 promoter was a positive control for p53 binding. 
The GAPDH promoter was a negative control. Similar 
input is seen for all samples, and IgG antibody control 
does not amplify (Fig 3K). Notch1 promoter primers 
show that more p53 binds to the promoter in MT/jnk2ko 
GFP cells than GFP-JNK2 cells, thus demonstrating that 
JNK2  dampens  p53  binding  to  the  Notch1 promoter. 
Experiments above support that less p53 binding to the 
Notch1 promoter in the presence of GFP-JNK2 occurs due 
to lower p53 expression.
Jnk2 loss in a p53ko model promotes 
tumor growth and luminal differentiation 
by augmenting BRCA1
We next performed mammary gland transplants 
of p53ko;jnk2wt and p53ko;jnk2ko tissue into wt mice 
to assess whether JNK2 controls tumor development or 




grow significantly faster than p53ko;jnk2wt tumors after 
palpation (Fig 4A, p < 0.0001). p53ko;jnk2ko tumors also 
exhibit  2.9  times  more  Ki-67  positive  cells  compared 
to p53ko;jnk2wt (Fig 4B, p = 0.0159). The JNK2 anti-
proliferative response seen with the p53ko model differs 
from that observed in the MT model expressing wildtype 
p53 [23]. These data  indicate  that JNK2 may influence 
tumor growth through various downstream targets 
including p53.
While others have observed that Notch1 increases 
cell proliferation, its expression is not statistically different 
in the p53ko tumors by microarray analysis (1.1-fold, FDR 
54%) or qPCR of  tumors  (Fig S3A, p = NS). Because 
these results may reflect the heterogeneity of the model, 
Notch1 promoter activity was measured in p53ko primary 
tumor  cells. GFP-JNK2  or GFP were  stably  expressed 
in a p53ko;jnk2ko cell line. Notch1 promoter activity is 
not changed by JNK2 in p53ko cells (Fig S3B, p = NS), 
supporting that p53 is required for JNK2 to reduce Notch1 
transcription.
Absence of jnk2 augments CK8/18+ populations 
and BRCA1 expression
As with MT tumors, a large proportion of cells within 
tumors do not stain positive for differentiation markers, but 
the proportion of CK8/18+ cells is significantly higher in 
p53ko;jnk2ko tumors compared to p53ko;jnk2wt (Fig 4C, 
p = 0.0159), akin to the normal mammary gland and MT 
tumors. Further, while expression of basal related genes, 
p63 and CK14, does not significantly differ, the luminal 
marker Brca1 is upregulated in the p53ko;jnk2ko tumors 
(Fig 4D, p = 0.05). BRCA1 expression also differs by 
tumor  microarray  (BRCA1  elevated  2.16-fold,  4.38% 
FDR) along with alterations in the ATM/BRCA1 pathway 
using GSEA analysis (Fig S3C, S3D). The p53ko;jnk2ko 
cell line was used to test if JNK2 alters lineage associated 
genes. Fig 4E shows that the GFP cells have significantly 
higher Brca1  mRNA  compared  to  GFP-JNK2  cells 
(p  =  0.0205).  BRCA1  protein  is  also  elevated  in  GFP 
cells  (Fig 4F). To  confirm  that BRCA1  transcription  is 
inhibited  by  JNK2, p53ko;jnk2ko GFP  and GFP-JNK2 
cells were transfected with a BRCA1 promoter plasmid 
or  promoterless  plasmid.  GFP-JNK2  reduces  BRCA1 
promoter activity compared to the GFP control (Fig 4G, 
p = 0.0127), supporting that BRCA1 is a JNK2 target in the 
absence of p53. Brca1 expression did not differ by qPCR 





To explore the mechanism of luminal cell 
suppression  by  JNK2,  we  considered  other  known 
mechanisms of differentiation in the normal mammary 
gland. BRCA1 controls the latter stages of luminal 
differentiation and its low expression is associated with 
EMT and stem cell populations. We used these gene 
signatures  to  test  whether  JNK2  prevents  tumor  cell 
differentiation. First, we examined if BRCA1 expression 
is negatively correlated with an EMT signature in human 
tumors. For this analysis, the average value of genes 
Figure 4: Absence of jnk2 increases the luminal cell population and BRCA1 expression in p53ko tumors. A. p53ko 
tumors were measured until reaching 1.5 cm diameter (n = 22 p53ko;jnk2wt, n = 18 p53ko;jnk2ko, Log rank test); B-C. p53ko tumors 
were immunostained and Ki-67+ and CK8/18+ cells were quantified (n = 5); D-E. Expression of basal (red) and luminal (blue) markers 
was measured in p53ko tumors (n = 8, E) and p53ko cell lines F. Western blot of BRCA1 expression in p53ko  cells; G. p53ko cells 
were transfected with Brca1 promoter (BRCA1PR) or promoterless control (PRless) luciferase plasmids and assayed for promoter 
activity; H. Correlation of Brca1 expression and EMT-related gene expression was assessed in human tumors (UNC308, n = 308, and 
COMBINED855, n = 855) and p53ko mouse tumors (n = 15, P.C. = Pearson Correlation). A nonparametric, two-tailed t-test was used 





















































COMBINED855 p53ko;jnk2wt + jnk2ko tumors












































































































































then the correlation between EMT and BRCA1 expression 
was plotted  in  our mouse  and human datasets.  Fig  4H 
shows a negative correlation between BRCA1 and EMT 
in  both  the UNC308  [28]  (Pearson  correlation −0.215, 
p  =  0.000147)  and  COMBINED855  [29]  (Pearson 
correlation −0.246, p = 2.75e−17) human datasets. Only a 
trend was observed in the relatively smaller number p53ko 
mouse tumors (Pearson correlation −0.444, p = NS). These 
data are in agreement with BRCA1 enhancing luminal 
differentiation.
Expression differences of select EMT-related 
genes were then explored by comparing p53ko;jnk2ko to 
p53ko;jnk2wt mouse tumors and the p53ko;jnk2ko GFP to 
GFP-JNK2 cell lines. Expression levels are heterogeneous, 
but p53ko;jnk2ko tumors show trends toward lower 
expression of mesenchymal transcription factors (Twist1, 
Snai1, Klf4, Zeb1, and Snai2) and significantly elevated 





blot,  showing  that  GFP-JNK2  only  slightly  increases 
JNK1 expression (Fig S4D). These data support that 
downregulation of Brca1  by  JNK2  is  associated  with 
EMT in the p53ko model and that a compensatory increase 
JNK1 expression is not observed in the absence of jnk2.
BRCA1 is sufficient to reduce JNK2 enriched 
tumor initiating cells
In spite of differences in EMT gene expression and 
luminal cell markers, a p53ko;jnk2wt and p53ko;jnk2ko 
tumor microarray failed to show a significant alteration 
of  differentiation  scores  on  a  transcriptome  level  [28]. 






Thus far our p53ko model indicates that 
JNK2  inhibits  luminal  cell  populations  by  expanding 
the EMT-expressing tumor initiating cell population. 
To  test  this  possibility,  we  measured  CD24  and 
CD49f to quantify putative tumor initiating cells. The 
CD24-/Lo population has been identified as an EMT/stem/
tumor initiating cell population in mouse mammary 
tumor models. CD49f expression is high in mammary 
stem cells and tumor initiating cells [31, 32], whereas 
CD44+ cells fail to show increased tumor formation in 
a limiting dilution assay in this model [33]. While CD49f 
positivity does not differ between GFP and GFP-JNK2 
cells,  CD24  expression  is  markedly  changed.  GFP 
cells are 98% CD49f+/CD24+ cells and 1.4% CD49f+/
CD24-  cells  versus  GFP-JNK2  cells  (21%  CD49f+/
CD24+ and 77% CD49f+/CD24-) (Fig 5A, p < 0.0001). 
Stable-expression of BRCA1 in GFP-JNK2 cells shifts 
the  CD24- population from 77% to < 1% (Fig 5A, 
p < 0.0001), consistent with its inverse correlation with 
EMT shown in Fig 4I. Interestingly, when GFP-JNK2 
cells are gated for medium and high GFP intensity, high 
JNK2 (GFP) expression occurs primarily in CD24- cells 
(Fig 5B).
The  CD24+ population is more differentiated 
than  the  CD24- population as shown by less Twist1 
(p = 0.05), Klf4 (p < 0.0001), and Snai2 (p = 0.0233) and 
higher Brca1 (p = 0.05), Ck14 (p = 0.0018) and Cdh1 
expression (p = 0.0131, Fig 5C). Gata-3 expression, a 
transcription factor expressed by luminal cells [34], was 
compared using RT-PCR. Its expression is also higher in 
the CD24+ population (Fig 5D, p = 0.0209). Using the 
GFP-JNK2 cells, two populations can be also visualized 
using vimentin and e-cadherin immunocytochemistry 
(Fig S5A). In bright field analysis, GFP-JNK2 cells are 
less contact inhibited than GFP cells, further supporting 
an EMT phenotype (Fig S5B). Similar relationships 
between  JNK2  expression  and  EMT/differentiation 
are  present  in MDA-231  and  21PT human  cell  lines. 
Here,  stable  expression  of  shJNK2  significantly 
decreases expression of SMA, a myoepithelial marker 
(Fig  5E).  shJNK2  expression  in  MDA-231  cells 
significantly  increases  EpCAMhi epithelial cells and 
decreases EpCAMneg/lo basal/mesenchymal populations 
(Fig 5F, p = 0.0013 and p < 0.0001). The EpCAMhi 
population  expresses  significantly  higher  levels  of 
Brca1 than the EpCAMneg/lo population (Fig 5G, 
p < 0.0001). Together,  these data maintain  that JNK2 
suppresses BRCA1-expressing epithelial populations 
and promotes an EMT phenotype in mouse and 
human cells.
The functional significance of JNK2 induced EMT 
was then tested with a limiting dilution tumor formation 
assay using p53ko;jnk2ko GFP or GFP-JNK2 cells. All 
mice developed palpable tumors when injected with 
104  cells  (Table  1).  However,  GFP  masses  remained 
relatively small, not reaching target size by 6 months. 
At 103 cells, 1 of 4 GFP-JNK2 injected mice developed 
a palpable tumor, but no GFP cell injected mice did. At 
102 cells, no mice experienced palpable tumors in either 
group. When euthanizing tumor bearing mice, internal 
organs and mammary glands were inspected for GFP+ 
foci. No metastases were observed in GFP cell injected 
mice, but two metastases were detected in GFP-JNK2 cell 
injected mice.
After 6 months of observation, some mice from each 
genotype remained tumor free. To explore if the injected 
cells were still viable but indolent, internal organs and 
mammary glands were examined for GFP. No foci were 
Oncotarget11871www.impactjournals.com/oncotarget
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Figure 5: JNK2 increases putative tumor initiating cells and inhibits ER expression in p53ko mouse and mutant 
p53-expressing human cells. A. CD24/CD49f staining was compared in p53ko cell lines by flow cytometry; B. The percentage of 
CD24- and CD24+ cells were assessed in p53ko;jnk2ko GFP-JNK2 cells that were gated for GFP expression (medium and high) by flow 
cytometry; C. CD24+ and CD24- populations in p53ko;jnk2ko GFP-JNK2 cells were separated by FACS and expression of EMT/stem (red) 
and differentiation (blue) markers measured by qPCR; D. CD24+ and CD24- populations in p53ko;jnk2ko GFP-JNK2 cells were tested 
for Gata-3 expression by RT-PCR; E. shJNK2 or GIPZ non-silencing plasmids were stably expressed in mutant p53-expressing MDA 231 
and 21PT cell lines. JNK2 and SMA expression were measured by western blot; F. MDA 231 cells were assessed for EpCAM and CD44 
expression; G. EpCAMhi and EpCAMneg/lo populations in MDA 231 cells were separated by FACS. Brca1 was measured by qPCR; H. Cell 
viability of p53ko cells was evaluated using MTT assay; I. p53ko cells were pulse labeled with BrdU. BrdU incorporation in CD24+ and 
CD24- populations was measured; J. Western blot of ER and PR expression in p53ko cells; K. p53ko cells were cultured with charcoal 
stripped serum (CSS), CSS + Estradiol (E2), or CSS + E2 + Fulvestrant (F) and ER expression was measured by western blot; L. p53ko 




detected in GFP cell injected mice, but one  contra-lateral 
gland metastasis was seen at 102 cell dose without a 
primary  tumor.  Five  tumors were  found  in GFP-JNK2 
injected mice, with one at 103 cells and four at 102 cells. 
A contralateral gland metastasis was seen in each of the 
103 and 102 cell dilutions and ascites developed in one of 
the 103 cell GFP-JNK2 group. Data from this experiment 
point toward the GFP cell line having approximately 
1 tumor initiating cell in 5,116 cells versus the GFP-
JNK2 cell line having 1 in 569 cells (Table 2, p = 0.0305, 
Pearson’s Chi-squared Test). This experiment shows that 
GFP-JNK2  promotes  tumor  initiating  cell  populations, 
which also possess a propensity to metastasize. These two 
properties likely result from JNK2 promoting EMT.
JNK2 inhibits tumor cell proliferation
As noted earlier, p53ko;jnk2ko tumors grow 
faster than p53ko;jnk2wt controls. In vitro proliferation 
is  also  inhibited  by  GFP-JNK2  in  p53ko;jnk2ko cells 
(Fig 5H, p = 0.0002). These findings are consistent with 
an EMT/tumor initiating cell population associated low 
proliferation  index. To examine  if  the  JNK2 effects on 
proliferation result from EMT, cells were pulse labeled 
with BrdU and sorted into CD24- and CD24+ populations. 
CD24+ populations from both genotypes incorporate 
BrdU  at  a  significantly  higher  frequency  than  CD24- 
populations (Fig 5I, p = 0.0089 for GFP and p < 0.0001 
for GFP-JNK2). Both the CD24+ and CD24- GFP-JNK2 
cells incorporate less BrdU compared to CD24+ and CD24- 
GFP (p < 0.0001),  indicating  that  JNK2  slows  in vitro 
proliferation in both an EMT dependent and independent 
fashion in the p53ko;jnk2ko cell line.
JNK2 reduces ER expression
In  rationalizing  how  the  CD24+ population 
displays a higher proliferation rate despite evidence 
of more luminal differentiation, we suspected that ER 
could modulate this response, in light of its elevated 
expression in GFP cells (Fig S4B). Indeed, GFP cells 
express more ER protein along with its target gene, 
progesterone receptor (PR) than GFP-JNK2 cells (Fig 5J). 






inhibits GFP cell viability on day 3 and 6 (p < 0.0023 and 
p = 0.0006, respectively), but it had no effect on GFP-
JNK2 cells (Fig 5L). These data show that JNK2 inhibits 
ER expression and ER associated proliferation.
The  potential  clinical  impact  of  JNK2  on  ER 
dependent tumor growth was then explored. GFP and 
GFP-JNK2 cells were injected into ovariectomized nu/nu 
mice one day after inserting estradiol pellets. Placebo or 
fulvestrant treatment was started upon tumor palpation. 
Table 2: JNK2 expression promotes tumor initiating cell populations in p53ko cells. Data from 
limiting dilution assay were used to calculate tumor initiating cell content in p53ko cell lines.
GFP GFP-JNK2
Frequency 1 in 5116 1 in 569
− S.E.M. 1 in 8605 1 in 937
+ S.E.M. 1 in 3042 1 in 346
Table 1: JNK2 promotes tumor growth and metastasis in p53ko cells. Limiting dilution assay was 





Palpated Tumors Indolent Tumors
GFP GFP-JNK2 GFP GFP-JNK2
Tumors Metastasis Tumors Metastasis Tumors Metastasis Tumors Metastasis
104 4/4 0/4 4/4 2/4 0/0 0/0 0/0 0/0
103 0/6 0/6 1/4 0/4 0/6 0/6 1/3 2/3*
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without fulvestrant (Fulv) for 48 hours. p-JNK (green) and ER (red) were detected using immunocytochemistry; D. Proposed model of the 
mechanism by which JNK2 inhibits luminal commitment of mammary epithelial cells. 
Surprisingly, while GFP associated masses became 
palpable they remained small for the duration of the 
experiment (Fig 5M), irrespective of treatment. In contrast, 
all  GFP-JNK2  tumors  eventually  reached  ≥  750 mm3. 
Placebo treated GFP-JNK2 tumors grew significantly more 
rapidly than the GFP placebo group (p = 0.0003, Day 15) 
but  grew  more  slowly  compared  to  the  GFP-JNK2 
tumors treated with E2+fulvestrant (p = 0.0215, Day 15) 
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(Fig 5M). Mice injected with GFP cells were treated 
until Day 32 at which point E2+fulvestrant significantly 
inhibited tumor size compared to placebo (p = 0.0002). No 
other comparisons reached statistical significance.
Tumors were harvested when reaching target 
size  or  on  Day  32  and  evaluated  histologically  using 
Hematoxylin/Eosin  (H/E)  stain. The GFP-JNK2  tumor 
cells constituted the majority of the large masses. 
Limited SMA+  myofibroblasts  and  collagen  (by 
Masson’s Trichrome  stain) were  located  at  the  tumors’ 
edge (Fig 6A). Within the tumor masses, abundant 
populations of vimentin and Transforming Growth Factor 
β1 (TGFβ1) positive tumor cells can be visualized. H/E 
staining  of  contralateral  glands  confirms  tumor  cells 
in the glands and lymph nodes. Notably, lymph node 
localized GFP-JNK2  tumor  cells  in  the E2+fulvestrant 
treatment group show classical signs of signet-ring cells 
where abundant intracellular mucin pushes the nucleus 
asymmetrically [35].
Only limited studies were completed on the GFP 
masses due to their small size. GFP related masses possess 
small clusters of GFP+ cells (Fig 6A). These cells are 
enmeshed within SMA+  myofibroblasts.  In  contrast 
to GFP-JNK2  tumors,  GFP  tumor  cells  are  e-cadherin 
positive and organize in pseudo-ductal patterns. Only 
a few cells stain positive for either vimentin or TGFβ1. 
These data indicate that while GFP cells activate 
fibroblasts and collagen deposition, an effect frequently 
associated with tumor development, they remain indolent 
or stationary for the remainder of the experiment.
Due  to  extensive fibrosis,  the GFP-related masses 
were resistant to homogenizing for protein isolation. 
Conversely, GFP-JNK2 tumors easily disaggregated and 
potential treatment related changes were evaluated between 
the placebo and E2+fulvestrant  treatment groups, which 
differed  significantly  in  their  growth  rates.  Fulvestrant 
stimulated growth has been previously attributed to 
elevated expression of ErbB family proteins [36]. 
Higher  ErbB2  expression  is  observed,  and  to  a  lesser 
extent  EGFR  expression,  in  the  E2+fulvestrant  tumors 
compared to placebo in our model (Fig 6B). No differences 




of cJun may result from higher RTK expression/
activity or, alternatively, result from RTK independent 
fashion since pERK remains unaffected. Through either 
mechanism, increased phosphorylated cJun suggests that 
fulvestrant+E2  induces  JNK2  activity  which,  in  turn, 
further promotes tumor progression. To more clearly assess 
whether fulvestrant induces ER degradation and/or JNK 
phosphorylation, cell lines were cultured in 5% FBS with or 
without fulvestrant 10-7M for 48 hrs. ER staining (in red) is 
reduced in fulvestrant treated cells as well as the abundance 
of pJNK (in green) in both cell lines (Fig 6C). These data 
further support that fulvestrant degrades ER protein but 
induces JNK activity in the GFP cells with pJNK signal 
likely originating from JNK1 isoforms.
Collectively, these data strongly validate a role 
for JNK2 in the suppression of luminal cell populations 
(Fig 6D). In the presence of p53, JNK2 inhibits Notch1 
expression, which reduces luminal cell populations. 
Alternatively,  JNK2  inhibits  luminal  commitment  in 
the absence of p53 by reducing Brca1 expression and 
promoting EMT associated tumor growth and progression.
DISCUSSION
Herein, we address the specific role of jnk2 in the 
mouse mammary gland and mammary tumors since 
previous work showed that high JNK2 tumor expression 
is associated with poorer disease free survival in patients 
with basal-like breast cancers [17]. JNK2 limits luminal 
cell populations in normal mammary and tumor cells, 
irrespective  of  p53  status.  These  findings  support  that 
JNK2 mediates EMT and promotes  tumor progression. 
Major efforts are underway to characterize mammary 
stem and progenitor cell populations to ultimately identify 
pathways involved in tumor development, recurrence and 
progression. JNK2 may prove to be one of the more global 
and easily targeted mediators identified thus far.
Notch1, p53, BRCA1, and ER play integral roles 
in normal mammary and tumor cell differentiation. 
Notch1  promotes  differentiation  but  requires  temporal 
regulation of other co-factors such as GATA-3 and 
BRCA1 to restrict and complete mammary luminal cell 
differentiation. In a biphasic nature, Notch1 stimulates 
stem cell differentiation and progenitor expansion. This 
may explain why Notch1 is preferentially up-regulated in 
some breast tumor models [7] where it may expand tumor 
cells lacking expression of more terminal differentiation 
genes [37]. A dose-dependent phenotype of Notch1ICD 
occurs in mammary cells grown in a 3D culture [38]. 
The higher levels of Notch1ICD expression are associated 
with small and abortive cultures, whereas lower levels of 
Notch1ICD are associated with large, hyperproliferative 
cultures. Our jnk2ko phenotype is reminiscent of the latter 
response, but high Notch1ICD is temporary and primarily 
localized in TEBs in normal mammary gland. This 
pattern of expression is consistent with the precocious 
pubertal phenotype in jnk2ko glands without a propensity 
to develop tumors. By contrast, models generating 
mammary-targeted supraphysiologic expression 
of activated Notch1display tumorigenesis through 
overgrowth of luminal progenitors [39, 40]. Since JNK2 
protein is present in both basal and luminal lineages, it 
could suppress Notch1 in both stem and progenitor type 
tumor cells. In our MT model, Notch1 transcription is 
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elevated in jnk2ko tumors in concordance with elevated 
portions of CK8/18+ tumor cells, suggesting a stronger 
influence on  luminal cell populations. A  larger  luminal 
target population in jnk2ko glands may augment tumor 
multiplicity resulting from oncogenic stimuli [3]. On the 
other hand,  the  lower proliferative  index of MT;jnk2ko 
tumors may result from higher p53 expression, replicative 
stress  or  reduced  cJun  activity  [23].  These  data  point 
to  JNK2  conveying  positive  or  negative  effects  on 
tumorigenesis that are context dependent. These effects 
should be considered for strategic therapeutic targeting.
In the p53ko model, expanded luminal cell 
populations are also observed in the absence of jnk2, 
most notably by JNK2 suppression of Brca1 expression, 
rather than Notch1. Alterations in Brca1 expression are not 
detected in the MT/jnk2ko tumors, potentially due to wt 
p53 inhibition of Brca1 expression [41, 42]. Thus, by using 
the p53ko model, the ability of JNK2 to constrain Brca1 
expression and BRCA1-dependent luminal commitment 
became evident. BRCA1 is a tumor suppressor that 
regulates DNA damage response. Microarray analysis 
further  identified  increased  expression  of  several 
other DNA damage related genes in p53ko;jnk2ko 
tumors. More rapid tumor growth was observed in 
p53ko;jnk2ko tumors and cell lines grown in vitro and 
coincided with  lower  expression  of  EMT markers  and 
higher  luminal marker expression. Several groups have 
noted a correlation between BRCA1 expression and 
luminal differentiation [1, 3, 9, 15, 16]. The ability of 
BRCA1 to mediate mammary tumor differentiation 
has been attributed to its inhibition of Slug (Snai2) 
and Twist  expression,  key mediators  of  EMT  [1]  [43]. 
Others have reported that BRCA1 promotes differentiation 
by de-repressing Polycomb-repressive complex 2 (PRC2) 
effects on differentiation genes [11]. Thus, inhibition 
of  BRCA1  may  be  a  mode  by  which  JNK2  counters 
mammary cell differentiation. Whether these BRCA1 
functions are related to its role in DNA damage is unclear.
In conditionally deleted jnk1koΔ/Δ jnk2ko mammary 
glands, others have also reported higher proliferation 
and increased branching. Transplanted jnk1koΔ/Δ;jnk2ko 
glands also generated more tumors when conditionally 
expressing K-RasG12D and p53Δ/Δ. Jnk  deficient  tumors 
were basal-like, based on limited lineage markers [44]. 
Implications of  these findings are unclear  since mutant 
K-Ras is uncommon in human breast cancer. This group 
also studied tumorigenesis in systemic p53ko;jnk1ko 
and p53ko;jnk2ko  mice,  but  no  significant  differences 
were observed in tumor-free survival between control and 
jnk-deficient mice. While p53+/-; jnk2ko mice experienced 
shorter tumor latencies and tumor-free survival associated 
with any tumor type [26]. These results bring into question 
the specific roles of the different JNK isoforms in various 
tissues. We observed no change in tumor latency in our 
models with jnk2 deficiency, but our approach  focused 
solely on mammary tumors by transplanting jnk2ko or 
jnk2wt mammary tissue into wildtype hosts.
Given  the  high  frequency  of  p53  inactivation 
in human tumors, our p53ko;jnk2ko mammary tumor 
model may prove clinically applicable for understanding 
mammary  tumor  biology.  It  reflects  the  ability  of 
JNK2 alone  to  regulate  a wide  spectrum of  tumor  cell 
differentiation  states.  Namely,  JNK2  enhances  EMT/
stemness, and conveys an ER unresponsive phenotype. 
The ability of JNK2 to significantly increase the CD24-  
tumor initiating cell population of a p53ko;jnk2ko cell 
line is also consistent with its differential regulation of 
BRCA1/ER and EMT. Further characterization of the 
p53ko;jnk2ko cells through limiting dilution assay showed 
that JNK2 induces tumor initiating cell populations which 
generate tumors that metastasize, in contrast to GFP 
masses that failed to progress.
To our  knowledge, we  are  the first  to  report  that 
JNK2  inhibits  ER  expression. To  better  appreciate  the 
potential  translational  impact of  these JNK2 associated 
changes,  we  tested  whether  E2  enhances  growth  of 
p53ko;jnk2ko  GFP  or  GFP-JNK2  tumors  which  could 
then be antagonized by fulvestrant. Unexpectedly, 
growth  rates  of  GFP  and  GFP-JNK2  tumors  starkly 
diverged where GFP-JNK2 expression accelerated tumor 
growth.  Histologically,  GFP  cells  cultivated  a  fibrotic 
microenvironment in the mammary fat pad, as expected, 
but tumor cells remained indolent (similar to the limiting 
dilution experiment), suggesting they are unresponsive 
to  the  activated  microenvironment.  This  insufficiency 
may arise due to their more differentiated phenotype and 
a low proportion of tumor initiating cells compared to 
GFP-JNK2  expressing  cells. Alternatively,  tumor  cells 
may require JNK2 activity to respond to critical integrin 
and RTK mediated cues from their microenvironment [45].
With regard to the influence of JNK2 on hormone 
responsiveness,  GFP  masses  were  significantly 
smaller  with  E2+fulvestrant  treatment  compared  to 
placebo (p  <  0.0002)  by  Day  32,  but  none  of  these 
tumors  grew  to  target  size,  making  this  finding  of 
debatable  impact.  More  notably,  GFP-JNK2  tumors 
grew  significantly  faster with E2+fulvestrant  treatment 
compared to their placebo control, consistent with 
others showing elevated JNK phosphorylation and high 
AP1 (Activator Protein-1) transcriptional activity with 
endocrine resistance [46–48]. AP1 interacts with ER to 
alter estradiol-mediated responses. AP1 also induces 
proliferation in response to a variety of stimuli including 
E2  [49].  In  our  model,  JNK2 expression prevents 
fulvestrant associated ER degradation perhaps limiting 
its  efficacy.  E2+fulvestrant  treatment  also  increased 
phosphorylation of cJun on its JNK sensitive residue, 
indicating that fulvestrant+E2 may directly stimulate JNK 
to promote tumor progression. Alternatively, higher ErbB2 
expression was  also  noted,  a  finding  reported  in  other 
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fulvestrant stimulated models [36], and may be the source 
of elevated p-cJun. Interestingly, cJun can induce ErbB2 
expression in association with other factors [50]. Thus, 
elevated ErbB2 expression and JNK2 activity in response 
to E2+fulvestrant may be closely interconnected.
Importantly, results obtained from our tumor cell 
lines somewhat diverge from our spontaneous tumor 
model from which these cells were derived in that 
p53ko;jnk2ko  tumors  grew  more  quickly.  One  must 
consider that the cell line is cultured in vitro which 
significantly lessens heterogeneity of the original tumor 
and  removes  the  microenvironment  related  influence. 
Also, the p53ko mammary tumor model is heterogeneous 
in  nature,  and  it  is  unlikely  that  any  one  cell  line will 
accurately reflect all aspect of this model. Reconstituting 
JNK2  expression  in  a  p53ko;jnk2ko cell line provides 
an opportunity  to  study  JNK2 specific  responses while 
minimizing unaccounted variables associated with the 
spontaneous tumor model.





inhibit metastasis or for endocrine resistant tumors. Newer 
compounds that covalently bind to JNK offer an improved 




All mouse experiments were performed in 
accordance with institutional and national guidelines 
and regulations. Animal procedures and experiments are 
pre-approved by the IACUC at the University of Texas, 
Austin. Balb/c p53ko mice were obtained from Dr. Dan 
Medina (Baylor College, Houston, TX) and jnk2ko mice 
from Dr. Lynn Heasley (University of Colorado, Aurora, 
CO)  [52]. MT  transgenic mice were obtained  from  the 
NCI Mouse Consortium [53]. MT and jnk2ko mice were 
backcrossed  >10  generations  to  Balb/c  background  as 
described [23].
Reagents
Unless otherwise stated, chemical reagents were 
purchased from Sigma. Antibodies used include Six1 
(Origene),  p63  (Millipore),  Ki67  (Neomarkers),  SMA 
(DakoCytomation),  Notch1  (Millipore).  Antibodies 
obtained from EBioscience are CD24-PECy7, CD49f-PE.  
Cell Signaling antibodies include MMP9, Cleaved 
Caspase-3, Notch1ICD,  E-cadherin,  GAPDH,  Vimentin, 
Lef-1, and Zeb1. Santa Cruz antibodies include BRCA1, 
CK8/18,  ER,  PR,  mouse  HRP-conjugated  secondary 




and  G.  Paolo  Dotto  [20].  Notch1  promoter  constructs 
were a kind gift from Dr. Takashi Yugawa [24]. BRCA1 
promoter  constructs  were  a  kind  gift  from  Dr.  Robert 





and mounted with  Permount  (Fisher  Scientific).  Slides 
were imaged using an Olympus MVX10 microscope and 
Image Pro Plus software (Media Cybernetics). Ductal 
extension was scored as the average distance of the five 
furthest traversed TEBs from a line drawn through the 
center of the lymph node, perpendicular to the direction 
of  extension.  Branching  and TEBs were  quantified  by 
counting individual structures per gland.




in 10mM Na Citrate. Tissue was permeabilized and 
treated with H2O2 before primary antibody incubation. 
Tissues were then treated according to ABC kit (Vector 
Labs)  and  DAB  substrate  kit  (Abcam)  directions 
and then mounted with VectaMount (Vector Labs). 
Tissues  for  immunofluorescence  (IF)  were  incubated 
with  fluorescently-labeled  secondary  antibodies  and 
mounted with VectaShield with DAPI (Abcam). Images 
were obtained using an Olympus CKX41 bright-
field  microscope  with  QCapture  Pro  software  (Media 
Cybernetics). IF images were obtained on an Eclipse 
TE200  microscope  (Nikon)  using  Image  Pro  Plus 
Software.
Primary mammary epithelial cell 
culture and imaging
Primary Mammary epithelial cells were isolated 
from 8–10 wk, virgin glands. Briefly, glands were minced 
and treated with collagenase. Mammary epithelial cell 
organoids were isolated by differential centrifugation and 
disaggregated with  0.025%  trypsin/EDTA  (Invitrogen). 
After  filtration,  mammary  epithelial  cells  were  grown 
on Matrigel (BD Biosciences) according to established 
protocols [55] [56]. Acinar diameters were measured from 
bright field images with QCapture Pro Software. IF images 
were obtained using an SP2 AOBS Confocal Microscope 
(Leica) as previously described [56].
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Cell lines and BRCA1 and GFP-JNK2 
expression 
MT/jnk2ko and p53ko;jnk2ko cell lines were derived 
from mammary  tumors  [23]. Cells were maintained  in 
DMEM/F12 (1:1) medium (Mediatech Inc) supplemented 
with 10% FBS (Gemini), 10 ug/ml insulin (Lilly), 5 ng/ml 
EGF (Peprotech), penicillin, and streptomycin (Life 
Technologies). The BRCA1 expression plasmid 
(Dr. Elledge) obtained through Addgene [57]. GFP-JNK2 
expression was performed as previously described [23].
Western blot and MTT assay
Assays were performed as published [17].
qPCR
RNA was isolated from mammary epithelial 
cells in 3D culture using Trizol Reagent (Invitrogen). 
Primers were designed using PerlPrimer. Expression was 
measured  by  the SYBR Green method  in  a Stratagene 
M  ×  3005  p  qPCR  Machine  (Agilent  Technologies). 
Relative expression was calculated using standard curves 
with MxPro Software (Agilent Technologies). All assays 
were performed in triplicate of each sample. In tumor 
studies, each individual tumor RNA sample was analyzed 
in triplicate and the means were grouped to assess overall 
gene expression effects.
Luciferase assay
Subconfluent MT/jnk2ko GFP and GFP-JNK cells 
were transfected with N1PR, N1PRp53mut, or N1PRless 
luciferase constructs and CMV-Beta-galactosidase. Cells 
were harvested using Reporter Lysis Buffer (Promega). 
Samples were read on a Synergy 4 Plate reader (BioTek).
p53ko mammary gland transplants
Mammary glands from sexually mature mice 
were transplanted into cleared fat pads of 3 wk wildtype 
females. Two weeks after transplantation, recipients were 
implanted with  pituitary  isografts within  the  kidney  as 
described [25]. Glands were palpated until tumors formed 
and reached target size of 1.5 cm diameter.
Flow cytometry
Single cell suspensions were isolated from 
mammary glands as above or from culture and incubated 
with antibodies as recommended by manufacturer. Labeled 
cells were run on Millipore Guava Easy Cyte 8HT or BD 
FACSAria II and analyzed using FloJo 9.3.1 software 
(Treestar Inc). All assays were performed in triplicate.
Microarray analysis
Total RNA was collected, purified, and hybridized 
to Agilent custom 4 × 180 K microarrays as previously 
described [58]. The microarray data were uploaded to the 
University of North Carolina Microarray Database (UMD) 
(https://genome.unc.edu/pubsup/breastGEO/clinicalData.
shtml) and to the Gene Expression Omnibus (GEO) under 
accession number GSE40226. Hierarchical clustering was 
performed using Gene Cluster 3.0 [59] and the data viewed 
using  Java  Treeview  version  1.1.5r2  [60].  Statistically 
significant expression changes between tumor genotypes 
were  determined  using  a  2-class  unpaired  significance 




Subconfluent  cells  were  incubated  with  BrdU 
for one hour and then stained with antibodies per 
manufacturer’s instructions.
Limiting dilution tumor assay
Cell lines were trypsinized and recovered in full 
media, passed through a 40 um cell strainer and counted. 




weekly.  L-Calc  v1.1  (Stemsoft  Software)  was  used  to 
determine tumor initiating cell frequency.
Chromatin immunoprecipitation assay
Cells  were  fixed  in  1%  formaldehyde.  Cross-
linking  reactions  were  stopped  and  centrifuged  cells 
were then lysed and chromatin was sheared by bath 
sonication. Samples were then centrifuged and chromatin-
containing supernate was divided for input, IgG 
negative control (Calbiochem), and p53 (Cell Signaling) 
immunoprecipitation  (IP).  Chromatin  was  IP’ed  with 
protein A  sepharose  beads  (Fisher  Scientific)  and  pre-
cleared with sonicated salmon sperm DNA (Amresco). 
Samples were washed with progressively higher salt 
solutions as previously described [61], and eluted 
from  beads.  Cross-links  were  reversed,  and  chromatin 
precipitated. After re-suspension, chromatin was treated 
with  Proteinase  K  (Fisher  Scientific).  After  digestion, 
DNA was isolated using a DNEasy kit (Qiagen) according 
to manufacturer’s  instructions. Samples were amplified 
30  cycles  by  PCR  using  specific  primers,  listed  in 
Supplemental procedures.
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injected into the number 4 mammary gland. When tumors 
became palpable, mice were injected subcutaneously with 
fulvestrant (5 mg) or placebo weekly [62]. Tumor volumes 
(volume = width2  ×  length/2)  were  measured  thrice 
weekly  and  harvested  ≥  750 mm3.  Tumors  were  flash-
frozen in  liquid nitrogen or fixed in 10% formalin prior 
to paraffin-embedding. Frozen tumors were homogenized 
in lysis buffer and subjected to SDS-PAGE, transferred to 
nitrocellulose and analyzed by immunoblot analysis.
Statistics
Statistical analyses were performed using Prism 
Software (GraphPad). A nonparametric, two-tailed t-test 
was  employed  to  determine  significance  between  two 
groups.  Significance  for  survival  data  was  determined 
using  Log-rank  test,  where  p < 0.05 was considered 
significant.  The  1-way  ANOVA  was  employed  to 
determine significance amongst multiple groups followed 
by post-hoc t-test to compare two samples. Error bars 
are shown as standard error of the mean. Significant data 
from t-tests are indicated on figures as follows: *p < 0.05, 
**p < 0.01, ***, p < 0.0001.
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